Literature DB >> 7608215

Determinants of thrombin receptor cleavage. Receptor domains involved, specificity, and role of the P3 aspartate.

K Ishii1, R Gerszten, Y W Zheng, J B Welsh, C W Turck, S R Coughlin.   

Abstract

Thrombin receptor cleavage at the Arg41- decreases -Ser42 peptide bond in the receptor's amino-terminal exodomain is necessary and sufficient for receptor activation. The rate of receptor cleavage at this site is a critical determinant of the magnitude of the cellular response to thrombin. These observations underscore the importance of defining the molecular basis for thrombin-receptor interaction and cleavage. We report that chimeric proteins bearing only thrombin receptor amino-terminal exodomain residues 36-60 are cleaved at rates similar to the wild-type thrombin receptor when expressed on the cell surface. A soluble amino-terminal exodomain protein was also cleaved efficiently by thrombin with a Km of 15-30 microM and k(cat) of approximately 50 s-1, with cleavage occurring only at the Arg41- decreases -Ser42 peptide bond. In the context of previous studies, these data suggest that the receptor's LDPR cleavage recognition sequence and DKYEPF hirudin-like domain account for thrombin-receptor interaction. Because a P3 aspartate in protein C's cleavage site inhibits cleavage by free thrombin, we investigated the role of the P3 aspartate in the receptor's LDPR sequence. Studies with mutant receptors revealed an inhibitory role for this residue only in the absence of the receptor's hirudin-like domain. These and other data suggest that the receptor's hirudin-like domain causes a conformational change in thombin's active center to accommodate the LDPR sequence and promote efficient receptor cleavage. Taken together, these studies imply that the thrombin receptor's amino-terminal exodomain contains all the machinery needed for efficient recognition and cleavage by thrombin. Thrombin appears to bind and cleave this domain independently of the rest of the receptor, with one thrombin molecule probably activating multiple receptors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7608215     DOI: 10.1074/jbc.270.27.16435

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

Review 1.  How the protease thrombin talks to cells.

Authors:  S R Coughlin
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

2.  Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin.

Authors:  M L Kahn; M Nakanishi-Matsui; M J Shapiro; H Ishihara; S R Coughlin
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

3.  Coupling of the thrombin receptor to G12 may account for selective effects of thrombin on gene expression and DNA synthesis in 1321N1 astrocytoma cells.

Authors:  G R Post; L R Collins; E D Kennedy; S A Moskowitz; A M Aragay; D Goldstein; J H Brown
Journal:  Mol Biol Cell       Date:  1996-11       Impact factor: 4.138

4.  Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46.

Authors:  Laurent O Mosnier; Ranjeet K Sinha; Laurent Burnier; Eveline A Bouwens; John H Griffin
Journal:  Blood       Date:  2012-11-13       Impact factor: 22.113

5.  Neuroinflammation-Induced Interactions between Protease-Activated Receptor 1 and Proprotein Convertases in HIV-Associated Neurocognitive Disorder.

Authors:  WooJin Kim; Erin Zekas; Robert Lodge; Delia Susan-Resiga; Edwidge Marcinkiewicz; Rachid Essalmani; Koichiro Mihara; Rithwik Ramachandran; Eugene Asahchop; Benjamin Gelman; Éric A Cohen; Christopher Power; Morley D Hollenberg; Nabil G Seidah
Journal:  Mol Cell Biol       Date:  2015-08-17       Impact factor: 4.272

Review 6.  Harnessing the platelet signaling network to produce an optimal hemostatic response.

Authors:  Lawrence F Brass; Maurizio Tomaiuolo; Timothy J Stalker
Journal:  Hematol Oncol Clin North Am       Date:  2013-04-11       Impact factor: 3.722

7.  Thrombin inhibits nuclear factor kappaB and RhoA pathways in cytokine-stimulated vascular endothelial cells when EPCR is occupied by protein C.

Authors:  Jong-Sup Bae; Alireza R Rezaie
Journal:  Thromb Haemost       Date:  2009-03       Impact factor: 5.249

Review 8.  Progress in the understanding of protease-activated receptors.

Authors:  Esteban C Gabazza; Osamu Taguchi; Haruhito Kamada; Tatsuya Hayashi; Yukihiko Adachi; Koji Suzuki
Journal:  Int J Hematol       Date:  2004-02       Impact factor: 2.490

9.  Interaction of thrombin with PAR1 and PAR4 at the thrombin cleavage site.

Authors:  Marvin T Nieman; Alvin H Schmaier
Journal:  Biochemistry       Date:  2007-06-27       Impact factor: 3.162

10.  Cloning and characterization of human protease-activated receptor 4.

Authors:  W F Xu; H Andersen; T E Whitmore; S R Presnell; D P Yee; A Ching; T Gilbert; E W Davie; D C Foster
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.